OSI Industries was founded in 1909 by a German immigrant to the United States by the name of Otto Kolschowsky. He started the company in Chicago but quickly expanded into new markets as it grew in popularity. By the 1970s, his sons, who had joined him in earlier years, were ready to hire some outside help, and they found Sheldon Lavin, who began to get to work with expanding the company overseas. OSI continues to grow its operations and offer its customers more every year and has made an exciting expansion to a facility in Toledo, Spain recently. In Spain, OSI Industries spent 17 million euros to add a high-capacity production line, which now allows it to produce 24,000 tons of chicken products compared to the 12,000 tons that it was capable of producing before.
On top of being able to offer its customers in the region with more chicken products, OSI has also been able to offer 20 new jobs as the factory expands. In total, the plant can now produce 45,000 tons of beef, port, and chicken products on an annual basis and is responsible for the employment of 160 workers. OSI Industries completed the additions to its existing plant due to research it had been doing that pointed out that a rising demand in Spain and Portugal for chicken products. Over the last few years, this demand has grown by 8% every year, and since OSI Industries is in business to please its customers, it has answered the demand.
The improvements have added 22,600 square feet to the plant and include a production hall, storage for much needed supplies, refrigeration for waste containers, a new test kitchen that will work to develop new products for the company, and much more. OSI Industries is headed up by its CEO, Sheldon Lavin, and its president, David McDonald, and McDonald commented that the expansion will help the company with its goal to improve its products in the region and to gain new customers. The plant has also been made more efficient by reducing its electricity consumption, and this is in line with the companies efforts to make their operations more sustainable.
Source of the article : http://www.fooddrink-magazine.com/sections/producers/1308-osi-group
Negative news headlines have been the order of the day for the gluteal augmentation industry. For a long time in history, this industry has been associated with a myriad of medical malpractices and accidents. A lot of cosmetic surgeries have turned into sheer failure due to negligence and greed associated with the medical experts. However, a new face for the industry is in the process of being restored with the efforts of ethical and innovative experts such as Dr. Mark Mofid.
Dr. Mofid trained as a surgeon at the Harvard and Johns Hopkins Universities. There, he gained extensive proficiency in matters related to human skin, fat and muscle structure. Through his research skills, Dr. Mark Mofid has always been in the quest for different and better ways of improving the practices of the gluteal augmentation industry.
Some of the unique things that have helped Dr. Mark Mofid to build a good reputation in the cosmetic medical community is his adherence to the medical principles and safety practices. Unlike many medical experts around the world, Dr. Mark Mofid is so keen on matters regarding patients’ safety. He always shuns greed and allows reason to guide him in his operations.
For instance, it’s very common to find patients in the cosmetic surgery industry asking for very risky surgeries but on the other hand are likely to earn the doctor a good chunk of money. In such a scenario, Mark Mofid’s priority is always the safety of the patient. He would never attempt to engage in an operation that he is sure would put the patient’s health at dander.
On the other hand, Dr. Mark Mofid has several other aspects that keep his reputation clean and consequently earns him a lot of trust from many people in America. One of them is his research-oriented approach to innovation. For the 8 years that the industry guru has been in practice, he has always believed in existence of endless opportunities for future improvements. This has seen him spend countless hours in constant research for new ways in which the gluteal augmentation industry can use to improve its practices. He has been researching in collaboration with other renowned experts in the industry, especially from Brazil.
Amicus Therapeutics treats rare diseases with biotechnology. Their interest in genetic diseases has led to numerous treatments including migalastat. Migalastat is a candidate for the treatment of Fabry disease, and is based on the genetic diagnosis of the individual. Another development of Amicus Therapeutics is called SD-101, and it has reached the later stages in its development. This has been designed for the Epidermolysis Bullosa disorder which affects the connective tissues. Amicus Therapeutics strives to help the individuals suffering from rare diseases, and some of their candidates are expected to be the first available on the market.
The employees of Amicus Therapeutics joined forces and decided to create a statement that would reflect their beliefs, and values. This provided a reminder of why they work so hard every day, and what they hope to achieve. These beliefs are critical in understanding the strength of the commitment, and depth of passion Reflected by the proud employees of Amicus Therapeutics. They believe fighting to find therapies to help individuals with rare diseases is worth every moment of effort it requires. They strive to ensure their therapies provide the highest quality of help for these individuals (Indeed).
Amicus Therapeutics is about the community, individuals affected by serious diseases, and their families. The employees serve with passion, duty, new ideas, and technologies. Their core values represent their dedication to the work they do, their ability to accept new ideas, and the value of taking a smart risk. Amicus Therapeutics is not afraid to ask the really hard questions, and never limit themselves to outdated thinking. When they make a mistake, they gain knowledge, and experience, and continue their forward momentum.
Amicus Therapeutics reached for the future with a strong belief in science, strategic partnerships, and their shareholders. They price their medications fairly, make them accessible, and are responsible for their actions. They understand their success in the future is based on honesty, accountability, and teamwork. They make the contribution of every individual count, and communicate with diversity, respect, and a health balance. Although the employees of Amicus Therapeutics have fun, they never shirk their responsibilities.
More at http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/
- Mark Holterman is a professor at the University of Illinois College Of Medicine, and he has worked there from 2011. Dr. Mark is also an attending pediatric surgeon at the Children’s Hospital of Illinois and Advocate Christ Children’s Hospital. Holterman has majored in pediatric surgery and is interested in research concerning obesity and novel cancer treatments as well as stem cell therapies and regenerative medicine.
Education and Career
Dr. Mark Holterman schooled at Yale University, where he majored in biology and graduated with honors before earning his MD and Ph.D. from the University of Virginia (LinkedIn). He later finalized a residency in general surgery at the University of Virginia Health Science and a fellowship at Children’s Medical Center through the University of Washington. Previously, Dr. Mark attended pediatric surgeon at Rush University Medical Center and also served at the Advocate Children’s Hospital as surgeon-in-chief.
Dr. Holterman’s Association with Sunshine Foundation
Given to his knowledge in regenerative therapies, Dr. Mark has helped in the founding of Cellular Therapies and the Sunshine Foundation. This idea was inspired by three individuals who had a successful cellular and regenerative therapy. One of the three persons received these regenerative therapies from Celltex Therapeutics, to treat dysautonomia and systemic juvenile idiopathic arthritis. Celltex uses stem cells, mesenchymal cell, during treatment. Mesenchymal stem cells are readily available in tissues across the human body but are plenty in fat tissues. The MSCs’ ability to flourish in various cells, such as muscle and bone, making them essential in improving healing, stopping cellular decay, combating inflammation, and formation of new blood vessels.
Dr. Mark Holterman Recognized
Dr. Mark Holterman has received several awards such as the Innovative Research Award by the American Diabetes Association. ADA is an organization focused on funding research, cures and preventive measures of diabetes. The group offers two different awards to professional; the Translational Science (ICTS) Award and the Basic Science (IBS) Award. The IBS is available to a faculty member at any level and given to a person who presents original and new hypothesis. ICTS awards are however granted to individuals whose researchers directly involve human data, subjects, and samples.
More about Dr. Mark Holterman https://www.osfhealthcare.org/physicians/profile/2358/mark-j-holterman-md-phd/